Circulatory dipeptidyl peptidase 3 (cDPP3) is a potential biomarker for early detection of secondary brain injury after aneurysmal subarachnoid hemorrhage

Delayed cerebral ischemia (DCI) is a common complication after aneurysmal subarachnoid hemorrhage (aSAH) that can culminate in secondary brain damage. Although it remains one of the main preventable causes of aSAH-related morbidity, there is still a lack of prognostic criteria for identification of patients at risk of developing DCI. Because elevated circulatory levels of the enzyme dipeptidyl peptidase 3 (cDPP3) were recently identified as a potential biomarker for outcome prediction in critically ill patients, we evaluated the time-course of changes in cDPP3 levels after aSAH.

Source: Journal of the Neurological Sciences - January 30, 2021 Category: Neurology Authors: Felix Neumaier, Christian Stoppe, Michael Veldeman, Miriam Weiss, Tim Simon, Anke Hoellig, Gernot Marx, Hans Clusmann, Walid Albanna Source Type: research